Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GammaCan International has reported progress in its VitiGam development program. The company has completed a series of significant animal experiments that confirmed the effectiveness of IgG preparations derived from vitiligo donors against melanoma cells. This is the basis for GammaCan's lead product, VitiGam.
Subscribe to our email newsletter
In a number of human melanoma model experiments, using SCID mice and the A375 human melanoma cell line, the company demonstrated that vitiligo-derived IgG preparations can prevent, in a statistically significant manner, the growth of subcutaneous melanomas (tumors). In these experiments, IgG preparations derived from vitiligo donors were compared to a variety of other IgG preparations and also compared to saline.
Steven Katz, chairman of the board and president of GammaCan, said: “Our data are highly encouraging in that they demonstrate, for the first time, in human melanoma models, anti-melanoma activity from IgG preparations derived from vitiligo donors. These positive results keep us on track to file our IND with the FDA in the near term.”